Snibe 新产业

China · Shenzhen

alternative to Roche cobas / Abbott Alinity / Siemens Atellica

MAGLUMI chemiluminescence immunoassay analyzers, from the benchtop X3 to the high-throughput X8, with reagents for thyroid, fertility, tumour-marker, infectious-disease and other assays. It sold 1,698 analyzers outside China in H1 2026.

Why it fits

In-Vitro Diagnostics
Global-ready

Regional alternatives

Product facts

Segment: In-Vitro Diagnostics
Role: Manufacturer

H1 2026 results (Aug 2026): revenue CNY 2.42B (+11%), overseas main-business revenue CNY 1.10B (+15%), with 1,698 analyzers sold overseas.

Market authorizations

United States

FDA 510(k) cleared: MAGLUMI X3 immunoassay analyzer with MAGLUMI 25-OH Vitamin D assay
K232587 · decided 2024-04-12 Source (checked 2026-10)

European Union

CE marked (IVDR): MAGLUMI X8 chemiluminescence immunoassay analyzer (Class A)
69471455X8GF Source (checked 2026-10)
CE marked (IVDR): MAGLUMI HIV, HBV, HCV and syphilis assays (Class D)
Source (checked 2026-10)

Verified records only; absence here does not mean a product is unauthorized.

Company & market

Parent company: Shenzhen New Industries Biomedical Engineering
Registered: Shenzhen
Listing: A-share
Ticker: 300832.SZ
Market cap / val. (USD): ~$5.9 B
Foreign-investable: No

Visit official site ↗ Compare with similar products →

A China-based alternative to

Roche Diagnostics Abbott Diagnostics Siemens Healthineers